30. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential ^{18}F-FDG PET. *J Nucl Med.* 2005;46:1144–1150.
31. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18] fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. *Mol Imaging Biol.* 2006;8:36–42.
32. Takeuchi N, Fukumoto M, Nishioka A, et al. Scintigraphic prediction of response to chemotherapy in patients with breast cancer: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. *Int J Oncol.* 2002;20:53–58.
33. Lacan G, Kesner AL, Gangloff A, et al. Synthesis of [^{18}F] 2-[(2-chloro-2′-fluoroethyl)amino]-2h-1,3,2-oxazaphosphorinane-2-oxide (^{18}F-fluorocyclophosphamide), a potential tracer for breast tumor prognostic imaging with PET. *J Labelled Comp Radiopharm.* 2005;48:635–643.
34. Papanastassiou Z, Bruni J, Potts Fernandes F, Levins P. Potential carcinolytic agents. III. Fluoronitrogen mustard analogs of cyclophosphamide. *J Med Chem.* 1966;9:357–359.
35. Gutman M, Couillard S, Labrie F, Candas B, Labrie C. Effects of the antiestrogen em-800 (sch 57050) and cyclophosphamide alone and in combination on growth of human zr-75-1 breast cancer xenografts in nude mice. *Cancer Res.* 1999;59:5176–5180.
36. Ludeman SM, Zon G, Egan W. Synthesis and antitumor activity of cyclophosphamide analogues: preparation, hydrolytic studies, and anticancer screening of 5-bromocyclophosphamide, 3,5-dehydrocyclophosphamide, and related systems. *J Med Chem.* 1979;22:151–158.
37. Boyd VL, Zon G, Himes VL, Stalick JK, Mighell AD, Secor HV. Synthesis and antitumor activity of cyclophosphamide analogues. 3. Preparation, molecular structure determination and anticancer screening of racemic cis- and trans-4-phenylcyclophosphamide. *J Med Chem.* 1980;23:372–375.
38. Ludeman SM, Boyd VL, Regan JB, Gallo KA, Zon G, Ishii K. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide. *J Med Chem.* 1986;29:716–727.
39. Glazman-Kusnierczyk H, Matuszyk J, Radzikowski C. Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds. *Immunopharmacol Immunotoxicol.* 1992;14:883–911.

Errata

The article "Lung Toxicity in Radioiodine Therapy of Thyroid Carcinoma: Development of a Dose-Rate Method and Dosimetric Implications of the 80-mCi Rule," by Sgouros et al. (*J Nucl Med*. 2006;47:1977–1984), contained substantive errors in the reported data. A corrected PDF version is available online at http://jnm.snmjournals.org/cgi/data/47/12/1977/DC1/1. The authors regret the errors.

The byline in "High-Dose Radioimmunotherapy with ^{90}Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment," by Cremonesi et al. (*J Nucl Med.* 2007;48:1871–1879), was incorrect. The corrected byline is as follows:

Marta Cremonesi[1], Mahila Ferrari[1], Chiara Maria Grana[2], Anna Vanazzi[3], Mike Stabin[4], Mirco Bartolomei[2], Stefano Papi[2], Gennaro Prisco[2], Pier Francesco Ferrucci[5], Giovanni Martinelli[3], and Giovanni Paganelli[2]